CAS Insight

molecules of the month

Compound 14

elective NNMT inhibitor

100-times higher inhibitory activity than original peptide

peptide library screening, de novo design and SBDD

J. Med. Chem.

Shionogi Pharmaceutical Research Center, Toyonaka, JP

Compound 14 Chemical Structure elective NNMT inhibitor - Shionogi Pharmaceutical Research Center, Toyonaka, JP
4 mins read

Context. “Compound 14” (Shionogi Pharmaceuticals) is a nicotinamide N-methyltransferase (NNMT) inhibitor. For some “difficult to drug” targets such as protein-protein interactions, peptides are attractive therapeutic modalities due to their high binding specificity and synthetic accessibility. Macrocyclization of peptides may help improve upon their typical drawbacks, such as poor stability and cell permeability; however, the therapeutic efficacy of macrocyclic peptides is also limited by their molecular sizes and polar surface areas. To address these issues, Shionogi scientists adopted a novel ″Peptide-to-Small Molecule″ strategy that was based on structural hopping of macrocyclic peptides into nonpeptide small molecules. To evaluate the strategy, NNMT, a widely expressed epigenetic enzyme that has been associated with several diseases, was used. Starting from a macrocyclic peptide hit…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: